1
|
Verger E, Selleret L, Nizard J, Bachelot A, Dubreuil S, Ciangura C. Recherche des facteurs associés à l’obtention d’une naissance chez des femmes en situation d’infertilité et d’obésité sévère : expérience du parcours OPIOM. NUTR CLIN METAB 2022. [DOI: 10.1016/j.nupar.2021.12.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Martinez Garcia M, Gil M, Pineda E, Martin Soberón M, Mesia Barroso C, Foro P, Capellades J, Sarmiento B, Bruna J, Verger E, Taus Garcia A, Alameda F, Hernandez Lain A, Velasco G, Sepulveda Sanchez J. GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Vilaseca I, Nogués-Sabaté A, Avilés-Jurado FX, Berenguer J, Grau JJ, Verger E, Nadal A, Muxí A, Bernal-Sprekelsen M, Blanch JL. Factors of local recurrence and organ preservation with transoral laser microsurgery in laryngeal carcinomas; CHAID decision-tree analysis. Head Neck 2018; 41:756-764. [DOI: 10.1002/hed.25422] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 07/09/2018] [Accepted: 09/24/2018] [Indexed: 12/27/2022] Open
Affiliation(s)
- Isabel Vilaseca
- Otolaryngology Department; Hospital Clínic; Barcelona Spain
- Head Neck Clínic; Agència de Gestió d'Ajuts Universitaris i de Recerca; Barcelona Catalunya Spain
- Institutd'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS); Barcelona Spain
- Faculty of Medicine; University of Barcelona; Barcelona Spain
| | - Anna Nogués-Sabaté
- Otolaryngology Department; Hospital Clínic; Barcelona Spain
- Head Neck Clínic; Agència de Gestió d'Ajuts Universitaris i de Recerca; Barcelona Catalunya Spain
| | - Francesc Xavier Avilés-Jurado
- Otolaryngology Department; Hospital Clínic; Barcelona Spain
- Head Neck Clínic; Agència de Gestió d'Ajuts Universitaris i de Recerca; Barcelona Catalunya Spain
- Institutd'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS); Barcelona Spain
- Faculty of Medicine; University of Barcelona; Barcelona Spain
| | - Joan Berenguer
- Institutd'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS); Barcelona Spain
- Faculty of Medicine; University of Barcelona; Barcelona Spain
- Radiology Department; Hospital Clínic; Barcelona Spain
| | - Juan José Grau
- Head Neck Clínic; Agència de Gestió d'Ajuts Universitaris i de Recerca; Barcelona Catalunya Spain
- Institutd'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS); Barcelona Spain
- Faculty of Medicine; University of Barcelona; Barcelona Spain
- Oncology Department; Hospital Clínic; Barcelona Spain
| | - Eugenia Verger
- Faculty of Medicine; University of Barcelona; Barcelona Spain
- Radiotherapy Department; Hospital Clínic; Barcelona Spain
| | - Alfons Nadal
- Faculty of Medicine; University of Barcelona; Barcelona Spain
- Pathology Department; Hospital Clínic; Barcelona Spain
| | - Africa Muxí
- Faculty of Medicine; University of Barcelona; Barcelona Spain
- Nuclear Medicine Department; Hospital Clínic; Barcelona Spain
| | - Manuel Bernal-Sprekelsen
- Otolaryngology Department; Hospital Clínic; Barcelona Spain
- Faculty of Medicine; University of Valencia; Valencia Spain
| | | |
Collapse
|
4
|
Balañá C, Alonso M, Hernandez-Lain A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M. Correction to: SEOM clinical guidelines for anaplastic gliomas (2017). Clin Transl Oncol 2018; 20:937. [PMID: 29858734 DOI: 10.1007/s12094-018-1904-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.
Collapse
Affiliation(s)
- C Balañá
- Institut Català Oncologia Badalona, Ct. Canyet, s/n, 08916, Barcelona, Spain.
| | - M Alonso
- Complejo Hospitalario Virgen del Rocío, Seville, Spain
| | | | - P Perez-Segura
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - E Pineda
- Hospital Clínic i Provincial, Barcelona, Spain
| | - A Ramos
- Hospital 12 de Octubre, Madrid, Spain
| | - A R Sanchez
- Complejo Asistencial Universitario de León, León, Spain
| | - P Teixidor
- Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
| | - E Verger
- Hospital Clínic i Provincial, Barcelona, Spain
| | - M Benavides
- Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain
| |
Collapse
|
5
|
Martinez Garcia M, Gil Gil MJ, Pineda Losada E, Velasco G, Alameda F, Taus A, Capellades J, Márquez-Martín A, Sarmiento B, Mesia Barroso C, Bruna Escuer J, Verger E, Hernandez-Lain A, Guzman M, Sepúlveda JM. GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotonib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB): Results of the dose-escalation phase. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Miguel J. Gil Gil
- Institut Català d'Oncologia, L'hospitalet De Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | - Manuel Guzman
- School of Biology, Complutense University, Madrid, Spain
| | | |
Collapse
|
6
|
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol 2018; 20:1529-1537. [PMID: 29737461 DOI: 10.1007/s12094-018-1883-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 04/23/2018] [Indexed: 11/29/2022]
Abstract
PURPOSE We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. PATIENTS AND METHODS We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy. RESULTS OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor. CONCLUSION In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
Collapse
Affiliation(s)
- C Balaña
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain.
| | - A Estival
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain
| | - I Teruel
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain
| | - M Hardy-Werbin
- Cancer Research Programm, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - J Sepulveda
- Medical Oncology Service, Hospital Universitario, 12 de Octubre, Madrid, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic Provincial, Barcelona, Spain
| | | | - O Gallego
- Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain
| | - R Luque
- Medical Oncology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - M Gil-Gil
- Medical Oncology Service, Institut Català d'Oncologia-IDIBELL, Hospitalet de Llobregat, Spain
| | - C Mesia
- Medical Oncology Service, Institut Català d'Oncologia-IDIBELL, Hospitalet de Llobregat, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Saragossa, Spain
| | - A Berrocal
- Medical Oncology Service, Hospital General Universitario de Valencia, Valencia, Spain
| | - P Perez-Segura
- Medical Oncology Service, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - R De Las Penas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - J Marruecos
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - R Fuentes
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain
| | - G Reynes
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J M Velarde
- Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain
| | - A Cardona
- Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia.,Foundation for Clinical and Applied Cancer Research, FICMAC, Bogotá, Colombia.,Biology Systems Department, Universidad el Bosque, Bogotá, Colombia
| | - E Verger
- Radiation Oncology Service, Hospital Clinic Provincial, Barcelona, Spain
| | - C Panciroli
- Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain
| | - S Villà
- Radiation Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
7
|
Balana C, Teruel I, Estival A, Verger E, Sepulveda J, Pineda E, Garcia MM, Gallego O, Luque R, Gil MG, Mesia C, Barco SD, Velarde JM, Mosquera JJG, Herrero A, Villa S, de las Penas R. ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F. Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Med 2017; 6:2858-2866. [PMID: 29105360 PMCID: PMC5727237 DOI: 10.1002/cam4.1242] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 09/22/2017] [Accepted: 09/25/2017] [Indexed: 01/01/2023] Open
Abstract
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5‐fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606–7.564; P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; P = 0.0001) but was similar for PsP and nP patients (P = 0.91). OS was shorter–though not significantly so—for PsP than nP patients (OS: 19.5 vs. 27.9 months; P = 0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P = 0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
Collapse
Affiliation(s)
- Carmen Balaña
- Medical Oncology, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain
| | | | | | - Anna Estival
- Medical Oncology, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain
| | - Josep Puig
- Imaging Research Unit, Institut de Diagnostic per la Imatge (IDI), Biomedical Research Institute (IDIBGI), Hospital Universitari Dr Josep Trueta, Girona, Spain
| | - Sira Domenech
- Radiology, Institut Diagnòstic per la Imatge (IDI), Badalona, Barcelona, Spain
| | | | | | | | | | - JoseMaria Velarde
- Statistics, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain
| | - Carlos Mesia
- Medical Oncology, IDIBELL, Institut Catala Oncologia (ICO), Hospitalet de LLobregat, Barcelona, Spain
| | - Rafael Fuentes
- Radiation Oncology, Institut Catala Oncologia (ICO), Girona, Spain
| | - Jordi Marruecos
- Radiation Oncology, Institut Catala Oncologia (ICO), Girona, Spain
| | - Sonia Del Barco
- Medical Oncology, Institut Catala Oncologia (ICO), Girona, Spain
| | - Salvador Villà
- Radiation Oncology, Statistics, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain
| | - Cristina Carrato
- Pathology, Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain
| | - Oscar Gallego
- Medical Oncology, Hospital de Sant Pau, Barcelona, Spain
| | - Miguel Gil-Gil
- Medical Oncology, IDIBELL, Institut Catala Oncologia (ICO), Hospitalet de LLobregat, Barcelona, Spain
| | | | | | | |
Collapse
|
9
|
Balañá C, Alonso M, Hernandez-Lain A, Hernandez A, Perez-Segura P, Pineda E, Ramos A, Sanchez AR, Teixidor P, Verger E, Benavides M. SEOM clinical guidelines for anaplastic gliomas (2017). Clin Transl Oncol 2017; 20:16-21. [PMID: 29058264 PMCID: PMC5785606 DOI: 10.1007/s12094-017-1762-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 10/04/2017] [Indexed: 11/29/2022]
Abstract
The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.
Collapse
Affiliation(s)
- C Balañá
- Institut Català Oncologia Badalona, Ct. Canyet, s/n, 08916, Barcelona, Spain.
| | - M Alonso
- Complejo Hospitalario Virgen del Rocío, Seville, Spain
| | | | | | - P Perez-Segura
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - E Pineda
- Hospital Clínic i Provincial, Barcelona, Spain
| | - A Ramos
- Hospital 12 de Octubre, Madrid, Spain
| | - A R Sanchez
- Complejo Asistencial Universitario de León, León, Spain
| | - P Teixidor
- Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain
| | - E Verger
- Hospital Clínic i Provincial, Barcelona, Spain
| | - M Benavides
- Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain
| |
Collapse
|
10
|
Gil-Gil M, Velarde J, Martinez-Garcia M, Gallego O, del Barco S, Pineda E, Mesia C, Estival A, Vilariño N, Marruecos J, Verger E, Craven J, Fuentes R, Lucas A, Macià M, Carrato C, Vidal N, Velasco R, Villa S, Balana C. Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Maslah N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia 2017; 31:1661-1670. [PMID: 28484264 DOI: 10.1038/leu.2017.139] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Revised: 04/10/2017] [Accepted: 04/24/2017] [Indexed: 12/11/2022]
Abstract
Malignant hematological diseases are mainly because of the occurrence of molecular abnormalities leading to the deregulation of signaling pathways essential for precise cell behavior. High-resolution genome analysis using microarray and large-scale sequencing have helped identify several important acquired gene mutations that are responsible for such signaling deregulations across different hematological malignancies. In particular, the genetic landscape of classical myeloproliferative neoplasms (MPNs) has been in large part completed with the identification of driver mutations (targeting the cytokine receptor/Janus-activated kinase 2 (JAK2) pathway) that determine MPN phenotype, as well as additional mutations mainly affecting the regulation of gene expression (epigenetics or splicing regulators) and signaling. At present, most efforts concentrate in understanding how all these genetic alterations intertwine together to influence disease evolution and/or dictate clinical phenotype in order to use them to personalize diagnostic and clinical care. However, it is now evident that factors other than somatic mutations also play an important role in MPN disease initiation and progression, among which germline predisposition (single-nucleotide polymorphisms and haplotypes) may strongly influence the occurrence of MPNs. In this context, the LNK inhibitory adaptor protein encoded by the LNK/SH2B adaptor protein 3 (SH2B3) gene is the target of several genetic variations, acquired or inherited in MPNs, lymphoid leukemia and nonmalignant hematological diseases, underlying its importance in these pathological processes. As LNK adaptor is a key regulator of normal hematopoiesis, understanding the consequences of LNK variants on its protein functions and on driver or other mutations could be helpful to correlate genotype and phenotype of patients and to develop therapeutic strategies to target this molecule. In this review we summarize the current knowledge of LNK function in normal hematopoiesis, the different SH2B3 mutations reported to date and discuss how these genetic variations may influence the development of hematological malignancies.
Collapse
Affiliation(s)
- N Maslah
- APHP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris, France.,Inserm UMRS 1131, IUH, Université Paris-Diderot, Paris, France
| | - B Cassinat
- APHP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris, France.,Inserm UMRS 1131, IUH, Université Paris-Diderot, Paris, France
| | - E Verger
- APHP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris, France.,Inserm UMRS 1131, IUH, Université Paris-Diderot, Paris, France
| | - J-J Kiladjian
- Inserm UMRS 1131, IUH, Université Paris-Diderot, Paris, France.,APHP, Centre d'investigations Cliniques, Hôpital Saint-Louis, Paris, France
| | - L Velazquez
- INSERM UMRS-MD1197, Institut André Lwoff/Université Paris XI, Hôpital Paul Brousse, Villejuif, France
| |
Collapse
|
12
|
Vargas A, Paulazo C, Oleaga L, Verger E. [Asymptomatic skull base metastases: clinical course and therapeutic alternatives]. Rev Neurol 2017; 64:201-204. [PMID: 28229440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
INTRODUCTION Skull base metastases (SBM) are an infrequent and late type of cancer progression that are associated to poor prognosis. Its clinical manifestations may be grouped in five clinical syndromes and radiotherapy is its more frequent treatment. Because of the improvement in imaging tests and the close follow up of cancer patients, SBM can be diagnosed incidentally. In this group the best option of treatment has not been established. AIM To analyze the clinical features and outcomes of patients with SBM diagnosed incidentally. PATIENTS AND METHODS Between January 2012 and December 2015, 31 patients with diagnoses of SBM from solid primary tumor were reviewed. RESULTS SBM were diagnosed due to skull base syndromes (n = 24) or incidentally (n = 7). Symptomatic patients were treated with radiotherapy. Patients diagnosed incidentally remained without symptoms of craneal base involvement during the follow up, although they frequently had other types of intracranial progression. A statistically significant difference in survival was observed between symptomatic and asymptomatic patients (p = 0.001). CONCLUSIONS The incidentally diagnosed SBM were frequently associated to other types of intracranial progression, limiting the options of treatment.
Collapse
Affiliation(s)
- A Vargas
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - C Paulazo
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - L Oleaga
- Hospital Clinic de Barcelona, Barcelona, Espana
| | - E Verger
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| |
Collapse
|
13
|
Verger E, Nielsen T, Chakaroun R, Aron-Wisnewsky J, Delaere F, Gausserès N, Clément K, Holmes B. Évaluation de la validité relative du questionnaire de fréquence alimentaire développé pour les sujets français de l’étude MetaCardis. NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2016.10.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Martinez-Garcia M, Pineda E, Del Barco S, Estival A, Verger E, Marruecos J, Gallego O, Gil M, Fuentes R, de Grigno JCBL, Lucas A, Macia M, Mesía C, Velarde J, García N, Villà S, Balana C. Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Gallego O, Estival A, Martinez-Garcia M, Pineda E, Gil M, Del Barco S, Marruecos J, Verger E, Fuentes R, Velarde J, Mesía C, Craven J, Rosell SB, Quintana C, De Huerta LP, Granell E, Gómez B, García N, Villà S, Balana C. Characteristics of gliobastomas (GBM) not resected (only biopsied) homogeneosuly treated with Stupp regimen. Results from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Estival A, Pineda E, Martinez-Garcia M, Marruecos J, Mesía C, Lucas A, Macia M, Gil M, Gallego O, Verger E, Del Barco S, Fuentes R, Craven J, García N, Villà S, Velarde J, Carrato C, Ribalta T, Arpi O, Balana C. MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Pineda E, Martinez-Garcia M, Estival A, Gil-Gil M, Del Barco S, Gallego O, Verger E, Marruecos J, Fuentes R, de Grigno JCB, Mesía C, García N, Alameda F, Velarde J, Pujol T, Oleaga L, Carrato C, Capellades J, Villà S, Balana C. Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Vargas A, Aya F, Capurro S, Conill C, Verger E. [Solitary brain lesion in patients with cancer]. Rev Neurol 2016; 63:190. [PMID: 27439489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Affiliation(s)
- A Vargas
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - F Aya
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - S Capurro
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - C Conill
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| | - E Verger
- Hospital Clinic de Barcelona, 08036 Barcelona, Espana
| |
Collapse
|
19
|
Martinez-Garcia M, Pineda E, del Barco S, Garcia N, Verger E, Mesia C, Estival A, Gallego O, Gil Gil MJ, Fuentes R, Craven J, Villà S, de la Iglesia N, Alameda F, Carrato C, Ribalta T, Velarde JM, Balana C. Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.2045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Sonia del Barco
- Institut Català d'Oncologia Hospital Universitari Josep Trueta, Girona, Spain
| | | | | | - Carlos Mesia
- ICO Institut Català d'Oncologia, Barcelona, Spain
| | - Anna Estival
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | | | | | | | - Salvador Villà
- Catalan Institute of Oncology - University Hospital Germans Trias i Pujol, Radiation Oncology Department, Badalona, Spain
| | - Núria de la Iglesia
- Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clínic Barcelona, Barcelona, Spain
| | | | | | | | | | - Carmen Balana
- Institut Catala Oncologia. Hospital Germans Trias I Pujol, Badalona/Barcelona, Spain
| |
Collapse
|
20
|
Pineda E, Martinez M, Alameda F, Garcia N, Verger E, de la Iglesia N, Mesia C, Gallego O, Estival A, Pujol T, Gil Gil MJ, Oleaga L, Capellades J, Carrato C, Ribalta T, Domenech S, Fuentes R, Velarde JM, Balana C. Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | - Núria de la Iglesia
- Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clínic Barcelona, Barcelona, Spain
| | - Carlos Mesia
- ICO Institut Català d'Oncologia, Barcelona, Spain
| | | | - Anna Estival
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | | | | | | | | | | | - Sira Domenech
- Hospital Germans Trias i Pujol, Badalona/Barcelona, Spain
| | | | | | - Carmen Balana
- Institut Catala Oncologia. Hospital Germans Trias I Pujol, Badalona/Barcelona, Spain
| |
Collapse
|
21
|
Balana C, Alameda F, de la Iglesia N, Capellades J, Martinez-Garcia M, Pineda E, Ribalta T, del Barco S, Gallego O, Arpi O, Garcia N, Mesia C, Carrato C, Domenech S, Verger E, Pujol T, Oleaga L, Camins A, Lopez R, De Quintana C. Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy—A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Carmen Balana
- Institut Catala Oncologia. Hospital Germans Trias I Pujol, Badalona/Barcelona, Spain
| | | | - Núria de la Iglesia
- Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology. Hospital Clínic Barcelona, Barcelona, Spain
| | | | | | - Estela Pineda
- Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | - Sonia del Barco
- Institut Català d'Oncologia Hospital Universitari Josep Trueta, Girona, Spain
| | | | - Oriol Arpi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | | | - Carlos Mesia
- ICO Institut Català d'Oncologia, Barcelona, Spain
| | | | - Sira Domenech
- Hospital Germans Trias i Pujol, Badalona/Barcelona, Spain
| | | | | | | | - Angels Camins
- Hospital de Bellvitge, IDIBELL, L'hospitalet De Llobregat, Spain
| | | | | |
Collapse
|
22
|
Diab M, Nguyen F, Berthaud M, Maurel C, Gaschet J, Verger E, Ibisch C, Rousseau C, Chérel M, Abadie J, Davodeau F. Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours. Vet Comp Oncol 2016; 15:932-951. [PMID: 27076401 DOI: 10.1111/vco.12233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 12/17/2015] [Accepted: 03/18/2016] [Indexed: 12/31/2022]
Abstract
We isolated 11 antibodies specific for canine CD138 (cCD138) to validate the interest of CD138 antigen targeting in dogs with spontaneous mammary carcinoma. The affinity of the monoclonal antibodies in the nanomolar range is suitable for immunohistochemistry and nuclear medicine applications. Four distinct epitopes were recognized on cCD138 by this panel of antibodies. CD138 expression in canine healthy tissues is comparable to that reported in humans. CD138 is frequently expressed in canine mammary carcinomas corresponding to the human triple negative breast cancer subtype, with cytoplasmic and membranous expression. In canine diffuse large B-cell lymphoma, CD138 expression is associated with the 'non-germinal center' phenotype corresponding to the most aggressive subtype in humans. This homology of CD138 expression between dogs and humans confirms the relevance of tumour-bearing dogs as spontaneous models for nuclear medicine applications, especially for the evaluation of new tumour targeting strategies for diagnosis by phenotypic imaging and radio-immunotherapy.
Collapse
Affiliation(s)
- M Diab
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| | - F Nguyen
- ONIRIS Nantes Atlantic National College of Veterinary Medicine, Food Science and Engineering, Nantes, France
| | - M Berthaud
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| | - C Maurel
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| | - J Gaschet
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| | - E Verger
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| | - C Ibisch
- ONIRIS Nantes Atlantic National College of Veterinary Medicine, Food Science and Engineering, Nantes, France
| | - C Rousseau
- ICO Integrated Center for Oncology, Nantes, France
| | - M Chérel
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France.,ICO Integrated Center for Oncology, Nantes, France
| | - J Abadie
- ONIRIS Nantes Atlantic National College of Veterinary Medicine, Food Science and Engineering, Nantes, France
| | - F Davodeau
- Nantes-Angers Cancer Research Center CRCNA/INSERM UMR892, Nantes, France
| |
Collapse
|
23
|
Vilaseca I, Blanch JL, Berenguer J, Grau JJ, Verger E, Muxí Á, Bernal-Sprekelsen M. Transoral laser microsurgery for locally advanced (T3-T4a) supraglottic squamous cell carcinoma: Sixteen years of experience. Head Neck 2016; 38:1050-7. [DOI: 10.1002/hed.24408] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2015] [Indexed: 01/01/2023] Open
Affiliation(s)
- Isabel Vilaseca
- Department of ORL-HNS; Hospital Clínic; Barcelona Spain
- ENT Surgical Oncology Section; Hospital Clínic; Barcelona Spain
- University of Barcelona Medical School; Barcelona Spain
| | - José Luis Blanch
- Department of ORL-HNS; Hospital Clínic; Barcelona Spain
- ENT Surgical Oncology Section; Hospital Clínic; Barcelona Spain
| | - Joan Berenguer
- Neuroradiology Section, Department of Radiology; Hospital Clínic; Barcelona Spain
| | - Juan José Grau
- Department of Medical Oncology; Hospital Clínic; Barcelona Spain
- University of Barcelona Medical School; Barcelona Spain
| | - Eugenia Verger
- Department of Radiation Oncology; Hospital Clínic; Barcelona Spain
| | - África Muxí
- Department of Nuclear Medicine; Hospital Clínic; Barcelona Spain
| | - Manuel Bernal-Sprekelsen
- Department of ORL-HNS; Hospital Clínic; Barcelona Spain
- University of Barcelona Medical School; Barcelona Spain
| |
Collapse
|
24
|
Aranda G, Enseñat J, Mora M, Puig-Domingo M, Martínez de Osaba MJ, Casals G, Verger E, Ribalta MT, Hanzu FA, Halperin I. Long-term remission and recurrence rate in a cohort of Cushing's disease: the need for long-term follow-up. Pituitary 2015; 18:142-9. [PMID: 24748528 DOI: 10.1007/s11102-014-0567-8] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE Transsphenoidal surgery is the procedure of choice in Cushing disease (CD), with immediate post-operative remission rates ranging between 59 and 94% and recurrence rates between 3 and 46%, both depending upon the definition criteria and the duration of the follow-up. Our aim was to assess the rate of remission, recurrence and persistence of the disease after the first treatment and to identify predictors of remission in the CD population of our center. METHODS Retrospective cohort study of the patients diagnosed of CD and with follow-up in our center between 1974 and 2011. We analyzed 41 patients (35 women and 6 men) with a mean age at diagnosis of 34 ± 13 years. The mean follow-up was 14 ± 10 years (range 1-37 years) and the median of follow-up period was 6.68 years. RESULTS Thirty-five (85.4%) patients underwent transsphenoidal surgery as first treatment option. Histopathological evidence of a pituitary adenoma was registered in 17 (48.5%) patients. Thirty-two (78%) patients achieved disease remission after the first treatment, 21 (65.6%) of them presented disease recurrence. Persistent disease was observed in 9 (22%) patients. Twelve (29.3%) subjects developed post-surgical adrenal insufficiency, 7 of which (70%) achieved stable remission. Two parameters were found to be significant predictors of remission after the first treatment: age at disease diagnosis and the development of adrenal insufficiency (cortisol <3 μg/dl) in the immediate post-operative state. CONCLUSIONS We report a high recurrence rate, at least partially attributable to the long follow-up time. Early post-surgery adrenal insufficiency predicts remission. Hypopituitarism was also very prevalent, and strongly associated with radiotherapy. These results lead us to the conclusion that CD needs a life-long strict follow-up.
Collapse
Affiliation(s)
- G Aranda
- Department of Endocrinology and Nutrition, Hospital Clinic, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Pineda E, Valduvieco I, Pujol T, Oleaga L, Ribalta T, Caral L, Gonzalez J, Boget T, Graus F, Verger E. P17.70 * CAN ELDERLY PATIENTS WITH GLIOBLASTOMA BENEFIT FROM CONVENTIONAL CHEMO-RADIOTHERAPY TREATMENT? Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2013; 25:216-25. [PMID: 24256848 DOI: 10.1093/annonc/mdt461] [Citation(s) in RCA: 223] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable, nonmetastatic locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN). This randomized, open-label, phase III clinical trial compared the efficacy between standard CCRT and two different induction chemotherapy (ICT) regimens followed by CCRT. PATIENTS AND METHODS Patients with untreated LASCCHN were randomly assigned to ICT (three cycles), with either docetaxel (Taxotere), cisplatin and 5-fluorouracil (TPF arm) or cisplatin and 5-fluorouracil (PF arm), followed by CCRT [7 weeks of radiotherapy (RT) with cisplatin 100 mg/m(2) on days 1, 22 and 43]; or 7 weeks of CCRT alone. The primary end points were progression-free survival (PFS) and time-to-treatment failure (TTF). RESULTS In the intention-to-treat (ITT) population (n = 439), the median PFS times were 14.6 (95% CI, 11.6-20.4), 14.3 (95% CI, 11.8-19.3) and 13.8 months (95% CI, 11.0-17.5) at TPF-CCRT, PF-CCRT and CCRT arms, respectively (log-rank P = 0.56). The median TTF were 7.9 (95% CI, 5.9-11.8), 7.9 (95% CI, 6.5-11.8) and 8.2 months (95% CI, 6.7-12.6) for TPF-CCRT, PF-CCRT and CCRT alone, respectively (log-rank P = 0.90). There were no statistically significant differences for overall survival (OS). Toxic effects from ICT-CCRT were manageable. CONCLUSION Overall, this trial failed to show any advantage of ICT-CCRT over CCRT alone in patients with unresectable LASCCHN.
Collapse
Affiliation(s)
- R Hitt
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Llorente R, Hernandez IR, Valduvieco I, Verger E, Langdon C, Castilla L, Berenguer J, Grau J. Compliance of induction chemotherapy followed by concurrent chemoradiation in locally advanced nasopharyngeal carcinoma. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
28
|
Ríos I, Castilla Bancayan L, Valduvieco Ruiz I, Caral L, Pujol T, Ribalta T, Pineda E, Verger E. Elderly patients with glioblastoma and only biopsy. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
29
|
Park CK, Kim YH, Kim JW, Kim TM, Choi SH, Kim YJ, Choi BS, Lee SH, Kim CY, Kim IH, Lee DZ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, Shonka NA, Kessinger A, Aizenberg MR, Weller M, Meisner C, Platten M, Simon M, Nikkhah G, Papsdorf K, Sabel M, Braun C, Reifenberger G, Wick W, Alexandru D, Haghighi B, Muhonen MG, Chamberlain MC, Sumrall AL, Burri S, Brick W, Asher A, Murillo-Medina K, Guerrero-Maldonado A, Ramiro AJ, Cervantes-Sanchez G, Erazo-Valle-Solis AA, Garcia-Navarro V, Sperduto PW, Shanley R, Luo X, Kased N, Sneed PK, Roberge D, Chao S, Weil R, Suh J, Bhatt A, Jensen A, Brown PD, Shih H, Kirkpatrick J, Gaspar LE, Fiveash J, Chiang V, Knisely J, Sperduto CM, Lin N, Mehta MP, Anderson MD, Raghunathan A, Aldape KD, Fuller GN, Gilbert MR, Robins HI, Wang M, Gilbert MR, Chakravarti A, Grimm S, Penas-Prado M, Chaudhary R, Anderson PJ, Elinzano H, Gilbert RA, Mehta M, Aoki T, Ueba T, Arakawa Y, Miyatake SI, Tsukahara T, Miyamoto S, Nozaki K, Taki W, Matsutani M, Shakur SF, Bit-Ivan E, Watkin WG, Farhat HI, Merrell RT, Zwinkels H, Dorr J, Kloet A, Taphoorn MJ, Vecht CJ, Bogdahn U, Stockhammer G, Mahapatra A, Hau P, Schuknecht B, van den Bent M, Heinrichs H, Yust-Katz S, Liu V, Sanghee K, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung AW, Gilbert MR, Kunz M, Armbruster L, Thon N, Jansen N, Lutz J, Herms J, Egensperger R, Eigenbrod S, Kretzschmar H, La CF, Tonn JC, Kreth FW, Brandes AA, Franceschi E, Agati R, Poggi R, Dall'Occa P, Bartolotti M, Di Battista M, Marucci G, Girardi F, Ermani M, Sherman W, Raizer J, Grimm S, Ruckser R, Tatzreiter G, Pfisterer W, Oberhauser G, Honigschnabel S, Aboul-Enein F, Ausch C, Kitzweger E, Hruby W, Sebesta C, Green RM, Woyshner EA, Suchorska B, Jansen NL, Janssen H, Kretzschmar H, Simon M, Hentschel B, Poepperl G, Kreth FW, Linn J, LaFougere C, Weller M, Tonn JC, Suchorska B, Jansen NL, Graute V, Eigenbrod S, Bartenstein P, Kreth FW, LaFougere C, Tonn JC, Hassanzadeh B, Tohidi V, Levacic D, Landolfi JC, Singer S, DeBraganca K, Omuro A, Grommes C, Omar AI, Jalan P, Pandav V, Bekker S, Fuente MIDL, Kaley T, Zhao S, Chen X, Soffietti R, Magistrello M, Bertero L, Bosa C, Crasto SG, Garbossa D, Lolli I, Trevisan E, Ruda R, Ruda R, Bertero L, Bosa C, Trevisan E, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bomprezzi C, Thomas AA, Dalmau J, Gresa-Arribas N, Fadul CE, Kumthekar PU, Raizer J, Grimm S, Herrada J, Antony N, Richards M, Gupta A, Landeros M, Arango C, Campos-Gines AF, Friedman P, Wilson H, Streeter JC, Cohen A, Gilreath J, Sageser D, Ye X, Bell SD, McGregor J, Bourekas E, Cavaliere R, Newton H, Sul J, Odia Y, Zhang W, Shih J, Butman JA, Hammoud D, Kreisl TN, Iwamoto F, Fine HA, Berriel LG, Santos FN, Levy AC, Fanelli MF, Chinen LT, da Costa AA, Bourekas E, Wayne Slone H, Bell SD, McGregor J, Bokstein F, Blumenthal DT, Shpigel S, Phishniak L, Yust-Katz S, Garciarena P, Liue D, Yuan Y, Groves MD, Wong ET, Villano JL, Engelhard HH, Ram Z, Sahebjam S, Millar BA, Sahgal A, Laperriere N, Mason W, Levin VA, Hess KR, Choucair AK, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WKA, Prados MD, Bruner JM, Ictech S, Nghiemphu PL, Lai A, Green RM, Cloughesy TF, Zaky W, Gilles F, Grimm J, Bluml S, Dhall G, Rosser T, Randolph L, Wong K, Olch A, Krieger M, Finlay J, Capellades J, Verger E, Medrano S, Gonzalez S, Gil M, Reynes G, Ribalta T, Gallego O, Segura PP, Balana C, Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Yun T, Lee JS, Lee SH, Kim W, Vogelbaum MA, Wang M, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brackman DG, Shrieve DC, Souhami L, Mehta MP, Leibetseder A, Wohrer A, Ackerl M, Flechl B, Sax C, Spiegl-Kreinecker S, Pichler J, Widhalm G, Dieckmann K, Preusser M, Marosi C, Sebastian C, Alejandro M, Bernadette C, Naomi A, Kavan P, Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Curry R, Joyce J, Rosenblum M, Jaffe E, Matasar M, Lin O, Fisher R, Omuro A, Yin C, Iwamoto FM, Fraum TJ, Nayak L, Diamond EL, DeAngelis LM, Pentsova E, Vera-Bolanos E, Gilbert MR, Aldape K, Necesito-Reyes MJ, Fouladi M, Gajjar A, Goldman S, Metellus P, Mikkelsen T, Omuro A, Packer R, Partap S, Pollack IF, Prados M, Ian Robins H, Soffietti R, Wu J, Armstrong TS, Nakada M, Hayashi Y, Miyashita K, Kinoshita M, Furuta T, Sabit H, Kita D, Hayashi Y, Uchiyam N, Kawakami K, Minamoto T, Hamada JI, Diamond EL, Rosenblum M, Heaney M, Carrasquillo J, Krauthammer A, Nolan C, Kaley TJ, Gil MJ, Fuster J, Balana C, Benavides M, Mesia C, Etxaniz O, Canellas J, Perez-Martin X, Hunter K, Johnston SK, Bridge CA, Rockne RC, Guyman L, Baldock AL, Rockhill JK, Mrugala MM, Beard BC, Adair JE, Kiem HP, Swanson KR, Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh JJ, Theeler BJ, Ellezam B, Melguizo-Gavilanes I, Shonka NA, Bruner JM, Puduvalli VK, Taylor JW, Flanagan E, O'Neill B, Seigal T, Omuro A, DeAngelis L, Baerhing J, Hoang-Xuan K, Chamberlain M, Batchelor T, Nishikawa R, Pinto F, Blay JY, Korfel A, Schiff D, Fu BD, Kong XT, Bota D, Omuro A, Beal K, Ivy P, Gutin P, Wu N, Kaley T, Karimi S, DeAngelis L, Pentsova H, Nolan C, Grommes C, Chan T, Mathew R, Droms L, Shimizu F, Tabar V, Grossman S, Yovino S, Campian J, Wild A, Herman J, Brock M, Balmanoukian A, Ye X, Portnow J, Badie B, Synold T, Lacey S, D'Apuzzo M, Frankel P, Chen M, Aboody K, Letarte N, Gabay MP, Bressler LR, Stachnik JM, Villano JL, Jaeckle KA, Anderson SK, Willson A, Moreno-Aspitia A, Colon-Otero G, Patel T, Perez E, Peters KB, Reardon DA, Vredenburgh JJ, Desjardins A, Herndon JE, Coan A, McSherry F, Lipp E, Brickhouse A, Massey W, Friedman HS, Alderson LM, Desjardins A, Ranjan T, Peters KB, Friedman HS, Vredenburgh JJ, Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh J, Welch MR, Omuro A, Grommes C, Westphal M, Bach F, Reuter D, Ronellenfitsch M, Steinbach J, Pietsch T, Connelly J, Hamza MA, Puduvalli V, Neal ML, Trister AD, Ahn S, Bridge C, Lange J, Baldock A, Rockne R, Mrugala M, Rockhill JK, Lai A, Cloughesy T, Swanson KR, Neuwelt AJ, Nguyen TM, Tyson RM, Nasseri M, Neuwelt EA, Bubalo JS, Barnes PD, Phuphanich S, Hu J, Rudnick J, Chu R, Yu J, Naruse R, Ljubimova J, Sanchez C, Guevarra A, Naor R, Black K, Mahta A, Bhavsar TM, Herath K, Huang C, McClain J, Rizzo K, Sheehan J, Chamberlain M, Glantz M, McClain J, Glantz MJ, Zoccoli C, Nicholas MK, Xie T, White D, Liker S, Gajewski T, Selfridge J, Piccioni DE, Zurayk M, Mody R, Quan J, Li S, Chen W, Chou A, Liau L, Green R, Cloughesy T, Lai A, Gomez-Molinar V, Ruiz-Gonzalez S, Valdez-Vazquez R, Arrieta O, Stenner JI. CLIN-NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Balana C, Gil Gil MJ, Reynes G, Capellades J, Ribalta T, Gallego O, Pérez Segura P, Verger E. A phase II multicentric study of sunitinib administered as upfront therapy in glioblastoma: A study by the GEINO group. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.2045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2045 Background: Sunitinib is a multitargeted tyrosine kinase inhibitor that has direct antitumor and antiangiogenesis activity through targeting VEGFR 1-2, PDGFR α-β, c-kit, bFGF, (CSF-1), FLT3 and RET. Experimental studies in GB mice showed angiogenic activity, prolonged survival and synergy with irradiation Methods: Eligible pts were ≤75 years with GB not amenable to resection, PS≥2, MMS ≥25. Treatment was sunitinib 37.5mg daily for 8 w before radiotherapy, during radiotherapy (60Gy, 6 w) and after radiotherapy until disease progression. Primary endpoint was overall response (OR) (RANO criteria) after 8 w of sunitinib treatment before radiotherapy. Secondary endpoints were % pts free of neurological deterioration before radiotherapy, % pts who completed radiotherapy, PFS, OS and 1-year survival. We used a Simon 2-stage design (12 →20) based on OR to calculate the number of patients needed to detect at least 10% of responses with α error of 0.05 and β error of 0.10. Twelve patients were included in the first phase and one response was needed to continue study accrual. Results: 12 pts were enrolled: 7 males, median age 65 years, PS≥1: 8pts, median MMS 26.5. Neurological deficit: 5pts, DXM treatment 10/12, non-EIDS 3/12. Treatment: 5 pts completed 8 w of therapy, 2pts completed 7 w, 4 pts ≤ 6w. Toxicity G3 and 4: diarrhea (1pt), asthenia (2pts), skin and EDDPP (2), mucositis (2), fatal CNS hemorrhage (1), hypercholesterolemia and hypertriglycemia (1). OR was 1/12 SD, 11/12 P; radiological response was SD in 5 pts but 4 pts progressed neurologically. Only 2 pts completed radiotherapy plus sunitinib. The only SD received treatment for 18 w. Median PFS was 7.5w (CI 95% 5.8-9.2), OS 16w (CI 95% 0.5-23.7), 1year OS: 0%. Conclusions: the trial was closed after the first stage due to lack of response. Sunitinib is an inactive agent in glioblastoma.
Collapse
Affiliation(s)
- Carmen Balana
- Institut Catala d'Oncologia Badalona, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Valduvieco I, Verger E, Oleaga L, Pujol T, Caral L, Ribalta T, Boget T, Pineda E, Graus F. PO-0650 ANALYSIS OF PERFUSION MAGNETIC RESONANCE CHANGES IN RADIATED WHITE MATTER IN PATIENTS WITH GLIOBLASTOMA. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70983-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Simó M, Velasco R, Graus F, Verger E, Gil M, Pineda E, Blasco J, Bruna J. Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. J Neurooncol 2012; 108:451-8. [PMID: 22407174 DOI: 10.1007/s11060-012-0836-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 02/15/2012] [Indexed: 01/01/2023]
Abstract
Epilepsy in glioblastoma multiforme (GBM) patients is common. Hematological toxicity is a potential side effect of antiepileptic drugs (AEDs) and a frequent limiting-dose effect of temozolomide (TMZ). The aim of the study was to investigate the impact of AEDs on thrombocytopenia in GBM patients treated with radiotherapy and TMZ. A cohort of 101 newly diagnosed GBM patients treated with radiotherapy and TMZ was reviewed. Clinical data, presence of seizures, AEDs use, platelet count, and accumulated TMZ dose were analyzed at each cycle. Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100.000/mm(3)). This cut-off represents the threshold beyond which TMZ treatment is modified. A linear and a probit pooled cross-sectional regression analysis were used to study the impact of age, gender, AEDs, and accumulated TMZ on thrombocytopenia. Impact of AEDs on survival was also analyzed. Thirty-five patients (35%) presented seizures at onset and 18 (27%) during follow-up. Seven (13%) needed two or more AEDs for seizure control. Grade 3-4 thrombocytopenia was found in 8%. Decrease in platelet count was related to accumulated TMZ (p < 0.001), age (p < 0.001), and valproate (p = 0.004). Platelet count <100.000/mm(3) was only associated with accumulated TMZ (p = 0.001). Recursive Partitioning Analysis prognostic class was the only variable with significant impact on survival. Valproate and age had an independent negative effect on total platelet count, although neither had an effect on critical thrombocytopenia (<100.000/mm(3)). Therefore, the systematic withhold of valproate in GBM patients might not be justified. Nevertheless, this negative effect may be taken into account especially in elderly patients.
Collapse
Affiliation(s)
- Marta Simó
- Neuro-Oncology Unit, Hospital Universitari de Bellvitge and ICO Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), C/Feixa Llarga s/n, 08907, L'Hospitalet del Llobregat, Spain
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Verger E, Valduvieco I, Caral L, Pujol T, Ribalta T, Viñolas N, Boget T, Oleaga L, Blanco Y, Graus F. Does gender matter in glioblastoma? Clin Transl Oncol 2012; 13:737-41. [PMID: 21975336 DOI: 10.1007/s12094-011-0725-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
BACKGROUND The clinical outcome of glioblastoma (GBM) patients who receive radiotherapy alone or with chemotherapy is well established. However, little is known about how many patients do not receive this treatment. We consider it is important to investigate why a proportion of operated patients do not receive further treatment after surgery. METHODS We reviewed all consecutive GBM patients operated on in our hospital between January 2000 and December 2008. RESULTS A total of 216 patients with GBM were identified. Fifty-five (25%) did not receive any treatment after surgery. Univariate analysis showed that factors associated with no further treatment after surgery were older than 60 years (p=0.002), of female gender (p=0.03), had a KPS<70 (p<0.001) and had had a biopsy (p<0.001). Multivariate analysis indicated that age =60 years and KPS <70 were independent predictors of no further treatment after surgery. Gender was not an independent variable. However, women in the whole series were older than 60 years (p=0.01), and they had a worse KPS (p=0.02) and more biopsies (p=0.04) than men. In the whole group, median survival time was 10.4 months for men (n=125) vs. 7.2 months for women (n=91), log rank p<0.04. This difference was not observed in the group that was treated after surgery. CONCLUSIONS One out of four patients could not be treated after surgery. Independent predictors were older age and low KPS. These poor risk variables were more frequent in women and their survival was therefore lower than men in our series.
Collapse
Affiliation(s)
- E Verger
- Institute of Haematology and Oncology, Department of Radiation Oncology, Hospital Clínic, University of Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Brell M, Castañer S, Pujol-Farré T, Boluda S, Ribalta T, Bruna J, Martínez M, Verger E, Villà S, Viñolas N, Gil M, Graus F, Tortosa-Moreno A. [Implication of radiological pattern in the prognosis of oligodendroglial tumors: correlation with genetic profile]. Rev Neurol 2011; 52:465-471. [PMID: 21425099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
INTRODUCTION 1p19q loss of heterozygosity (LOH1p19q) in oligodendroglial tumors has shown to be prognostic of prolonged survival and predictive of therapeutic responsiveness. During the last years, research is actively being directed to the discovery of radiological characteristics related to LOH1p19q. AIMS. To confirm the existence of molecular heterogeneity in oligodendroglial tumors in relation to their anatomic distribution, and to evaluate the correlation between molecular profile and other radiological and clinical characteristics and their prognostic impact. PATIENTS AND METHODS Fifty-four patients with oligodendroglial tumors managed according to a previously established protocol were included. Preoperative SE T1, T1 post-gadolinium and T2 magnetic resonance images were reviewed by two independent neuroradiologists, blinded to clinical and molecular information. LOH analysis was assessed from paired tumor-blood DNA acid samples. RESULTS LOH1p was highly associated with LOH19q (p < 0.0001), LOH1p (odds ratio, OR = 6.19; 95% confidence interval, 95% CI = 1.66-22.68; p = 0.004), LOH19q (OR = 7.59; 95% CI = 1.84-31.34; p = 0.006) and LOH1p19q (OR = 5.38; 95% CI = 1.51-19.13; p = 0.007) were found to be more frequent in tumors located in the frontal lobe. Frontal location (hazard ratio, HR = 4.499; 95% CI = 1.027-193.708; p = 0.046), ring enhancement (HR = 0.213; 95% CI = 0.065-0.700; p = 0.011) and extent of resection (HR = 9.231; 95% CI = 1.737-49.050; p = 0.009) resulted independent prognostic factors for overall survival in the multivariate analysis. CONCLUSIONS Glioma classification aims to better define patients prognosis. Besides histological and immunohistochemical analyses, molecular information has become of great importance. Our results indicate that the evaluation of some MR features may also be useful. Efforts must be directed toward the use of every available resource at each institution.
Collapse
Affiliation(s)
- Marta Brell
- Servicio de Neurocirugía, Hospital Universitario Son Dureta, Palma de Mallorca, España
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
De Neve M, Sioen I, Boon P, Arganini C, Moschandreas J, Ruprich J, Lafay L, Amiano P, Arcella D, Azpiri M, Busk L, Christensen T, D’addezio L, Fabiansson S, Hilbig A, Hirvonen T, Kersting M, Koulouridaki S, Liukkonen KH, Oltarzewski M, Papoutsou S, Rehurkova I, Ribas-Barba L, Serra-Majem L, Tornaritis M, Trolle E, Van Klaveren J, Verger E, Walkiewicz A, Westerlund A, De Henauw S, Huybrechts I. Harmonisation of food categorisation systems for dietary exposure assessments among European children. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2010; 27:1639-51. [DOI: 10.1080/19440049.2010.521957] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Grau JJ, Tagliapietra A, Verger E, Caballero M, Muñoz C, Alos L. Prognostic significance of epithelitis by concurrent cetuximab and radiotherapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC) patients (Pts). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Villa S, Weber DC, Moretones C, Manes A, Puyalto P, Cuadras P, Bruna J, Verger E, Graus F, Balana C. Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Abstract
CONCLUSIONS Weekly paclitaxel may be an active and well tolerated chemotherapy regimen for patients with platin-resistant advanced head and neck cancer. OBJECTIVES Weekly paclitaxel should be an active and well tolerated regimen for palliative treatment of platin-resistant patients with recurrent or metastatic carcinoma of the head and neck. We analyzed the antitumor activity and toxicity profile. PATIENTS AND METHODS Sixty consecutive patients with advanced head and neck cancer were treated with 1 h infusion of paclitaxel, 80 mg/m(2) weekly, for 6 consecutive weeks. Patients who showed disease response or disease stabilization continued until progression of disease. RESULTS A total of 719 doses of paclitaxel were administered to the 60 patients. No complete response was observed. Partial response and stable disease were observed in 26 (43.3%) and 9 (15%) patients, respectively. Median time to tumor progression for patients who responded to therapy was 6.2 months (SD=1.3; 95% CI, 3.7-8.6) and the overall median survival in this group of patients was 8.5 months (SD=1.4; 95% CI, 5.7-11.2). The main toxic effects were leukopenia (26.6%), anemia (43.3%), fatigue (37.4%), alopecia (18.7%), rash/desquamation (13.3%), and thrombophlebitis (6.8%).
Collapse
Affiliation(s)
- Juan José Grau
- Oncology Department, Institut Clinic de Malalties Hemato-Oncologiques, University of Barcelona, Augusto Pi i Sunyer Memorial Institute for Biomedical Research, Hospital Clinic of Barcelona, Villarroel St 170, Barcelona, Spain
| | | | | | | | | |
Collapse
|
39
|
Grau JJ, Caballero M, Verger E, Blanch JL. Actual proportion of patients (pts) receiving chemotherapy or cetuximab for head and neck squamous carcinoma (HNSC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e17058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17058 Background: With the new indications of chemotherapy or cetuximab in HNSC, the rate of pts receiving these therapies nowadays is unclear. Methods: This retrospective study identified all consecutive pts with HNSC from January 1, 2006, to December 31, 2007, presented in a multidisciplinary team to decide further treatment in a single institution. ASCO guidelines for larynx preservation were followed to select surgery or chemoradiotherapy (ChRt). We classified the intention-to-treat as palliative, adjuvant or induction therapy. In the last case, always with concomitant radiotherapy (Rt) or prior to concomitant ChRt. Cetuximab was indicated with Rt as induction therapy for pts with problems to receive platin-based chemotherapy. Results: : A total of 350 pts were identified, 320 were male (91%), and 30 female (9%), with mean age 60.4 (range 41–90). Primary tumor was located in glottis (41%), supraglottis (19%), hypopharynx (11%), oropharynx (20%), or mouth (9%). Staging was I (27%), II (22%), III (16%), or IV (35%). Surgery alone was performed in 136 pts (39%) and chemotherapy or cetuximab in 214 other pts (61%). The intention-to-treat was palliative in 69 (32%), adjuvant in 51 (24%), or induction 94(44%) of the pts respectively. Rt plus cetuximab was administered to 31/97 (33%) and Rt plus chemotherapy in 63/97 (67%) pts as induction therapy. During this 2-year period, some pts received both induction/adjuvant and palliative chemotherapy. Conclusions: Chemotherapy or cetuximab is indicated as part of treatment in more than a half of pts with HNSC. Induction therapy is the most frequent indication. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. J. Grau
- Hospital Clinic, Barcelona, Spain; Hospital Clinic Barcelona, Barcelona, Spain
| | - M. Caballero
- Hospital Clinic, Barcelona, Spain; Hospital Clinic Barcelona, Barcelona, Spain
| | - E. Verger
- Hospital Clinic, Barcelona, Spain; Hospital Clinic Barcelona, Barcelona, Spain
| | - J. L. Blanch
- Hospital Clinic, Barcelona, Spain; Hospital Clinic Barcelona, Barcelona, Spain
| |
Collapse
|
40
|
Jorcano S, Farrús B, Pujol T, Verger E, Marruecos J, Conill C. Brain nodules with lung mass: are they always metastases? Clin Transl Oncol 2008; 10:512-4. [DOI: 10.1007/s12094-008-0241-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Grau JJ, Caballero M, Verger E, Monzo M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2008. [DOI: 10.1080/00016480802590451] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Grau JJ, Monzo M, Vargas M, Jansa S, Campayo M, Alos L, Domingo-Domenech J, Verger E. Single nucleotide polymorphisms (SNPs) analysis of CYP2C8, GSTT1, GSTP1, MDR1(A), MDR1(B) and ERCC1 as predictor of survival after weekly paclitaxel for relapsed advanced head & neck cancer patients (AHNCP). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2540 Background: Gene SNPs correlate with survival in cancer patients (pts) treated with chemotherapy (CHM). CYP2C8 and GSTT1, GTSP1 genes are involved in phase 1 and 2 drug cellular metabolisms respectively; MDR1(A) and MDR1(B) are involved in drug membrane transport and ERCC1 in DNA repair Methods: We evaluated the presence of SNPs of these 6 genes and the survival of AHNCP treated with weekly paclitaxel, 80 mg/m2 iv for 6 weeks. Responding pts continue CHM till progression. All pts were cisplatin resistant and no other local therapies were available. We analysed paraffin-embedded biopsies from 47 consecutive AHNCP for SNPs of the mentioned genes. The status of the alleles wild type (wt) or at least 1 SNP was compared with response rate (RR), time to progression (TTP) and overall survival (OS) Results: Of 47 pts, 43 were male and 4 female. The median of age was 57 yr (46–80). RR was 45% (21/47) and the TTP in responders was 5 months of median. OS for all pts was 5.6 months. Wild type vs at least 1 SNPs frequencies according the genes were: CYP2C8 23/24; GSTT1 45/2; GSTP1 36/11; MDR1(A) 21/28; MDR1(B) 13/34; and ERCC1 27/20. OS was significantly better in pts with 2 or more SNPs accumulated (p=0.0455). No other significant differences were observed in RR, TTP or OS in SNPs vs wild type pts. Conclusions: SNPs of CYP2C8, MDR1(A) and MDR1(B) genes were more frequent than wt in our pts. OS was significantly better in pts with 2 or more SNPs accumulated. Paclitaxel provides high rate of responses of short duration in AHNC pts No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. J. Grau
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - M. Monzo
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - M. Vargas
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - S. Jansa
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - m. Campayo
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - L. Alos
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - J. Domingo-Domenech
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - E. Verger
- Hospital Clinic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| |
Collapse
|
43
|
Conill C, Marruecos J, Verger E, Berenguer J, Lomeña F, Domingo-Domènech J, Grau JJ, Casas F. Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer. Clin Transl Oncol 2007; 9:172-6. [PMID: 17403628 DOI: 10.1007/s12094-007-0031-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Intramedullary spinal cord metastases (ISCM) are uncommon and present with rapidly progressing neurological deficits. The objective of this study was to determine the rate, duration of neurological response and survival after radiation therapy. We have retrospectively reviewed the clinical outcome of six cases with a diagnosis of ISCM from primary lung cancer, non-small cell (NSCLC) (n=3) and small cell (SCLC) (n=3). Total radiation dose ranged from 27 Gy/5 fr to 40 Gy/20 fr. Ambulation was preserved in 3 patients and partially recovered in one. Five out of the six patients (83%) showed improvement in neurological signs/symptoms with a mean duration of 17.2 days (max: 40 days; min: 6 days). Median survival time was 5 months (confidence interval (CI) 95%: 0-12) for NSCLC and 5 months (CI 95%: 4-6) for SCLC. Although radiation response rate is high, the interval free of neurological progression is very short. A therapeutic approach should be considered for each individual.
Collapse
Affiliation(s)
- C Conill
- Department of Radiation Oncology, Institute of Hematology and Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
BACKGROUND Lip cancer is frequently treated with surgery although radiation therapy offers comparable results. The aim of the study was to evaluate the local cure rate in patients with lip carcinoma treated with 192-Ir low dose rate interstitial brachytherapy. METHODS Fifty-four patients with a mean age of 70 years (range, 40-90 years) were retrospectively evaluated. The tumour location was the superior lip in 4 (7.4%) and the inferior lip in 50 (92.6%). Tumour stage was T1N0 in 33 patients and T2N0 in 21 patients. The radioactive sources with hypodermic needles in 49 patients (90.7%) and plastic tubes in 5 (9.3%) were placed parallel and equidistant from one another across the tumour volume according to the Paris system rules. RESULTS The median dose was 61.5 Gy (range, 60-65 Gy). All patients experienced acute brisk skin and mucositis RTOG grade III around the implanted volume, subsiding within 4-6 weeks after the implant. Local control was achieved in 98% of patients. The mean follow-up was 7 years. CONCLUSIONS Low dose rate interstitial brachytherapy with 192-Iridium is a well established and efficacious way to achieve local control of the tumour in lip cancer. It offers the advantage of avoiding surgery in an elderly population.
Collapse
Affiliation(s)
- C Conill
- Institute of Haematology and Oncology, Department of Radiation Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
| | | | | | | | | |
Collapse
|
45
|
Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F. Prognostic Significance ofO6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas. Clin Cancer Res 2005; 11:5167-74. [PMID: 16033832 DOI: 10.1158/1078-0432.ccr-05-0230] [Citation(s) in RCA: 155] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Anaplastic gliomas constitute a heterogeneous group of tumors with different therapeutic responses to adjuvant chemotherapy with alkylating agents. O6-Methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, is one of the implicated factors in glioma chemoresistance. The prognostic value of MGMT remains controversial due in part to the fact that previous published studies included heterogeneous groups of patients with different tumor grades. The aim of this study was to evaluate the prognostic significance of MGMT in patients with anaplastic glioma. EXPERIMENTAL DESIGN Ninety-three patients with anaplastic glioma were analyzed for MGMT protein expression by immunohistochemistry. In addition, for those patients from whom a good yield of DNA was obtained (n = 40), MGMT promoter methylation profile was analyzed by methylation-specific PCR. MGMT prognostic significance was evaluated together with other well-known prognostic factors. RESULTS Fifty-one tumors (54.8%) showed nuclear staining of MGMT. There was a trend towards longer overall survival for those patients with negative MGMT immunostaining (hazard ratio, 1.66; P = 0.066). In a secondary analysis including those patients who actually received chemotherapy (n = 72), the absence of MGMT expression was independently associated with better survival (hazard ratio, 2.12; P = 0.027). MGMT promoter methylation was observed in 50% of the analyzed tumors. No statistical correlation between MGMT expression and MGMT promoter hypermethylation was observed. CONCLUSIONS Unlike previous studies, we did not find a correlation between MGMT promoter methylation and survival. However, we observed a correlation between MGMT protein expression and survival in those patients who received chemotherapy thus suggesting that the absence of MGMT expression is a positive predictive marker in patients with anaplastic glioma.
Collapse
Affiliation(s)
- Marta Brell
- Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Marmol M, Pomes J, Muñoz M, Macho J, Blasco J, Combalia A, Farrus B, Verger E, Tomàs X, Gascon P. Vertebroplastia in patients with tumour injury of the vertebral body; therapeutic effect and short term complications. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - J. Pomes
- Hospital Clinic, Barcelona, Spain
| | - M. Muñoz
- Hospital Clinic, Barcelona, Spain
| | - J. Macho
- Hospital Clinic, Barcelona, Spain
| | | | | | | | | | - X. Tomàs
- Hospital Clinic, Barcelona, Spain
| | | |
Collapse
|
47
|
Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 2004; 59:501-8. [PMID: 15145169 DOI: 10.1016/j.ijrobp.2003.11.001] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2003] [Revised: 11/03/2003] [Accepted: 11/04/2003] [Indexed: 10/26/2022]
Abstract
PURPOSE To assess the long-term survival and prognostic factors associated with the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) and BVAM chemotherapy regimens followed by cranial radiotherapy in the treatment of primary central nervous system (CNS) non-Hodgkin lymphoma. METHODS AND MATERIALS Since 1986, high-dose methotrexate (1.5 g/m(2)), cytarabine, vincristine, and carmustine have been used in the BVAM chemotherapy regimen for primary CNS non-Hodgkin's lymphoma, with one cycle of CHOD given before BVAM in patients <or=70 years of age from 1990 onward. RESULTS The median age for the 77 patients treated was 60 years and the median follow-up of surviving patients was 3 years (range, 1.4-15.2 years). The complete response rate after chemotherapy was 62% and after additional radiotherapy was 73%. Multivariate analysis of overall survival showed age (p = 0.004), performance status (p = 0.007), and number of tumors (unifocal disease vs. multifocal disease; p = 0.005) to be statistically significant prognostic factors. Survival decreased with increasing age and performance status score. Using a prediction score giving 1 point for each adverse prognostic factor (age >or=60 years, performance status >or=2, and multifocal and/or meningeal disease [advanced stage]), a score of 0 (8 patients) was associated with a median survival of 55 months, a score of 1 (29 patients) of 41 months, a score of 2 (28 patients) of 32 months, and a score of 3 (12 patients) a median survival of 1 month (p <0.001). The actuarial overall survival for the 35 patients aged <60 years was 32.4% (95% confidence interval, 14.1-50.8%) at 10 years. CONCLUSION The Nottingham/Barcelona prediction score, which is similar to the International Prognostic Index, may be useful in comparing survival with different regimens studied in Phase II trials. Patients with primary CNS non-Hodgkin's lymphoma aged <60 years treated with CHOD/BVAM or BVAM followed by radiotherapy have a similar long-term survival to that of patients with large B cell non-Hodgkin's lymphoma at other extranodal sites.
Collapse
Affiliation(s)
- Eric M Bessell
- Department of Clinical Oncology, Nottingham City Hospital, Nottingham City, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
48
|
Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J. Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology 2002; 63:338-45. [PMID: 12417788 DOI: 10.1159/000066226] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVES To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy. METHODS Two hundred and four out of 1,089 patients analyzed met the defined criteria. All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue). Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion. A total of 418 cycles were given to 204 patients (mean 2.049 per patient). Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed. RESULTS One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial. One hundred ninety-four patients (95%) completed 2 courses of chemotherapy. After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery. Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients. Disease-free survival rates at 5 years were 26 and 22%, respectively. A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013). Causes of death were relapses in local area (86%), regional nodes (10.5%) or distant metastases (3.5%). Eleven patients (5%) died of a second primary. The main toxic effects were vomiting in 9% of patients and hemolytic-uremic syndrome in 3% of the patients treated with bleomycin. CONCLUSIONS In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy. In this study, patients have an acceptable long-term survival.
Collapse
Affiliation(s)
- Juan J Grau
- University of Barcelona, Medical Oncology Department, Institut de Malalties Hemato-Oncològiques, Hospital Clinic de Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Viñolas N, Gil M, Verger E, Villá S, Pujol T, Ceral L, García M, Graus F. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs 2002; 13:163-7. [PMID: 11901309 DOI: 10.1097/00001813-200202000-00008] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We undertook a phase II trial in 17 patients with malignant glioma and large measurable disease to assess response rate and survival with pre-irradiation chemotherapy, using higher doses than standard, trying to improve the outcome. Patients characteristics were: male/female 10/7, age 49 (range 23-59), median Karnofsky index 90% (range 70-100), glioblastoma multiforme/anaplastic astrocytoma 14/3. Treatment consisted of 2 cycles of carboplatin 200 mg/m(2) days 1-3 (or AUC x 8, total dose) plus cyclophosphamide 1000 mg/m(2) days 1-3. One partial response (6.5%) and two stabilizations (13.5%) were observed after pre-irradiation chemotherapy. Twelve out of 15 patients (80%) progressed after chemotherapy. Median survival time was 7.6 months and the survival at 1 year was 33%. Main toxicity was hematologic in the first cycle: neutropenia grade 4 in 100%; thrombocytopenia grade 4 in 73% and grade 3 in 27%; anemia grade 3 in 7%; in the second cycle: neutropenia and thrombocytopenia grade 4 in 100% and anemia grade 3 in 50%). No toxic death was related to treatment. This regimen showed limited activity in malignant glioma with large residual disease after surgery or biopsy.
Collapse
Affiliation(s)
- N Viñolas
- Institut Clinic de Malalties Hemato-Oncológique, Hospital Clinic, University of Barcelona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Bessell EM, López-Guillermo A, Villá S, Verger E, Nomdedeu B, Petit J, Byrne P, Montserrat E, Graus F. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20:231-6. [PMID: 11773174 DOI: 10.1200/jco.2002.20.1.231] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To assess the effect of a reduced dose of radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) regimen. PATIENTS AND METHODS Patients received one cycle of CHOD and two of BVAM. In the first trial, all 31 patients received 45-Gy whole-brain RT (CHOD/BVAM I). In the second, with 26 patients, RT dose was reduced to 30.6 Gy if there was a complete response (CR) after chemotherapy (CHOD/BVAM II). RESULTS Age, performance status, and chemotherapy received were similar in both protocols. CR rate at the end of all treatment was 68% for CHOD/BVAM I and 77% and for CHOD/BVAM II. Treatment modality was the only predictor of relapse, with 3-year relapse risks of 29% and 70% for CHOD/BVAM I and II, respectively. This was specifically important in the 25 patients less than 60 years old (3-year relapse risk, 25% v 83%; P =.01). The 5-year overall survival (OS) was 36%. Age (< 60 v > or = 60 years) was the only predictor for OS in the multivariate analysis (relative risk, 2.1; 95% confidence interval, 1.4 to 2.8). RT dose was the only predictor of OS in patients younger than 60 years old who achieved CR at the end of all treatment (3-year OS, 92% v 60% for patients receiving 45 or 30.6 Gy, respectively; P =.04). CONCLUSION Reduction of the RT dose from 45 Gy to 30.6 Gy in patients younger than 60 years old with PCNSL who achieved CR resulted in an increased risk of relapse and lower OS.
Collapse
Affiliation(s)
- E M Bessell
- Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|